TrialBMC cancer2016

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Markus Moehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.